Aerosol Biology Small Animal Models

气溶胶生物学小动物模型

• 批准号: 8446491
• 负责人: Robert MARK Buller
• 金额: $ 38.96万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-01 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8446491
• 关键词: A Mouse; A/J Mouse; Aerosols; Alanine Transaminase; Animal Model; Animals; Antigens; Antiviral Agents; Award; Bacillus anthracis; Basic Science; Biological Assay; Biology; Biotechnology; Blood; CD8B1 gene; Categories; Cells; Clinical; Country; Development; Disease; Disease Progression; Early Intervention; Ectromelia; Emerging Communicable Diseases; Genome; Hamsters; Health; Histology; IACUC; Immune response; Infection; Infectious Agent; Intervention; Laboratories; Learning; Licensure; Modeling; Modified Vaccinia Virus Ankara; Monkeypox; Monkeypox virus; Mouse Pox Virus; Mus; Myoxidae; Natural Killer Cells; Orthopoxvirus; Phase I Clinical Trials; Preclinical Testing; Protocols documentation; Public Health; Qualifying; Reporting; Research; Research Personnel; Respiratory System; Respiratory tract structure; Route; SARS coronavirus; Sampling; Services; Smallpox; Specimen; T-Lymphocyte; Telemetry; Temperature; Testing; Therapeutic; Tissues; Treatment Efficacy; Vaccinia virus; Viral; Virus; Work; Writing; aerosolized; biodefense; cytokine; efficacy testing; granulocyte; immunosuppressed; in vivo; influenzavirus; institutional biosafety committee; monocyte; pathogen; prophylactic; protocol development; respiratory; sample collection; surgical service; weapons

During the first award period the MRCE Aerosol Biology/Small Animal Models Core D (Core D) supported smallpox disease research (using ectromelia, monkeypox, and vaccinia viruses) as this disease was one of the most intensely modeled in Region 7. With licensure of Modified Vaccinia Ankara (MVA) and the availability of ACAM 2000¿ (derived from Dryvax¿), and phase I clinical trials of orthopoxvirus antivirals, ST-246 and CMX001, there is a diminishing need for in vivo testing of additional orthopoxvirus therapeutics and prophylactics. There is, however, still much to learn concerning the innate immune response to orthopxviruses and other infectious agents. The capacity of Core D to create additional models for use in basic research and prophylactic and therapeutic efficacy testing was under-scored by the development of the following five lethal challenge models: influenza virus A in C57BL/6-sfaH

在第一个奖项期间，MRCE气溶胶生物学/小动物模型核心D（核心D）支持 天花疾病研究（使用鼠痘，猴痘和牛痘病毒），因为这种疾病是 在第七区建模最密集。随着许可证的修改牛痘安卡拉（MVA）和 ACAM 2000的可用性（来自Dryvax），以及正痘病毒抗病毒药物的I期临床试验， ST-246和CMX 001，对另外的正痘病毒治疗剂的体内测试的需要逐渐减少 和物理学。然而，关于先天免疫反应， 正病毒和其他传染性病原体。核心D创建其他模型的能力， 基础研究和预防和治疗效果测试被开发的 以下5种致死性攻毒模型：C57 BL/6-sfaH中的流感病毒A